According to the company, the products are advanced wound care dressings that create a moist wound healing environment, deactivate harmful wound proteases and promote tissue growth in chronic wounds, which affect an increasingly large number of patients and have a serious impact on their quality of life.
The products will be marketed by Smith & Nephew under the terms of exclusive worldwide sales, marketing and distribution agreement announced in 2007.
Frank DiCosmo, president and CEO of Covalon, said: “Clinicians participating at a clinical in-market study indicated that these new collagen dressings facilitate granulation and epidermal migration as the majority of patients experienced a reduction in wound areas and an increase in the percentage of epithelial tissue over time.”